Duchenne Muscular Dystrophy (DMD) impacts millions globally, necessitating a robust market for effective treatments. The existing DMD treatment landscape is characterized by an focus on symptom management and supportive care. However, recent advances in gene therapy and drugs are creating the way for promising curative treatments. Research are act